SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-039201
Filing Date
2023-08-11
Accepted
2023-08-11 09:27:38
Documents
18
Period of Report
2023-08-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20057386_8k.htm   iXBRL 8-K 49259
2 EXHIBIT 5.1 brhc20057386_ex5-1.htm EX-5.1 14910
3 EXHIBIT 10.1 brhc20057386_ex10-1.htm EX-10.1 360700
4 EXHIBIT 10.2 brhc20057386_ex10-2.htm EX-10.2 105935
5 EXHIBIT 99.1 brhc20057386_ex99-1.htm EX-99.1 166071
9 image01.jpg GRAPHIC 149230
10 image02.jpg GRAPHIC 5725
  Complete submission text file 0001140361-23-039201.txt   1166143

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ocup-20230810.xsd EX-101.SCH 3865
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20230810_lab.xml EX-101.LAB 22546
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20230810_pre.xml EX-101.PRE 16044
12 EXTRACTED XBRL INSTANCE DOCUMENT brhc20057386_8k_htm.xml XML 4086
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

IRS No.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 231161845
SIC: 2834 Pharmaceutical Preparations